Medical

BAY 12-9566

A novel inhibitor of matrix metalloproteinases with antiangiogenic activity, which made it to phase-III trials for managing advanced pancreatic cancer but proved inferior to gemcitabine (4-month survival vs 7-month survival, respectively), the agent against which is was being compared, and subsequently has been abandoned.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.